LON:CREO

Creo Medical Share Forecast, Price & News

GBX 200.70
+6.70 (+3.45 %)
(As of 05/7/2021 03:49 PM ET)
Add
Compare
Today's Range
197.18
202
50-Day Range
194
226
52-Week Range
135.06
243
Volume9,693 shs
Average Volume111,555 shs
Market Capitalization£316.99 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CREO News and Ratings via Email

Sign-up to receive the latest news and ratings for Creo Medical and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Devices
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1291-606005
Employees175
Year FoundedN/A

Sales & Book Value

Annual Sales£8,154.00
Price / Sales38,874.86
Cash FlowGBX 44.33 per share
Book ValueGBX 47.80 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap£316.99 million
Next Earnings DateN/A
OptionableNot Optionable

Headlines

See More Headlines

About Creo Medical

Creo Medical Limited engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom. It is developing Speedboat RS2, a medical instrument through a combination of bipolar radiofrequency and microwave energy in a single platform for tissue dissection, resection, ablation, and coagulation. Creo Medical Limited was formerly known as MicroOncology Ltd. The company was founded in 2003 and is headquartered in Chepstow, the United Kingdom. Creo Medical Limited is a subsidiary of Creo Medical Group plc.

MarketRank

Overall MarketRank

0.50 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Creo Medical (LON:CREO) Frequently Asked Questions

What stocks does MarketBeat like better than Creo Medical?

Wall Street analysts have given Creo Medical a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Creo Medical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Creo Medical's earnings last quarter?

Creo Medical Limited (LON:CREO) released its quarterly earnings data on Wednesday, September, 23rd. The company reported ($6.00) earnings per share for the quarter.
View Creo Medical's earnings history
.

How has Creo Medical's stock been impacted by Coronavirus (COVID-19)?

Creo Medical's stock was trading at GBX 143.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CREO stock has increased by 39.9% and is now trading at GBX 200.70.
View which stocks have been most impacted by COVID-19
.

Who are Creo Medical's key executives?

Creo Medical's management team includes the following people:
  • Mr. Craig Jonathan Gulliford, CEO & Exec. Director (Age 50, Pay $694.95k)
  • Prof. Christopher Paul Hancock, Founder, CTO & Exec. Director (Age 53, Pay $567.24k)
  • Mr. Richard John Rees, CFO, Company Sec. & Exec. Director (Age 44, Pay $553.28k)
  • Mr. David Gerard Woods, Chief Commercial Officer & Exec. Director (Age 55)
  • Mr. Phil Hales, Sales & Marketing Director

Who are some of Creo Medical's key competitors?

What other stocks do shareholders of Creo Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Creo Medical investors own include MySQUAR (MYSQ) and IQE (IQE).

What is Creo Medical's stock symbol?

Creo Medical trades on the London Stock Exchange (LON) under the ticker symbol "CREO."

How do I buy shares of Creo Medical?

Shares of CREO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Creo Medical's stock price today?

One share of CREO stock can currently be purchased for approximately GBX 200.70.

How much money does Creo Medical make?

Creo Medical has a market capitalization of £316.99 million and generates £8,154.00 in revenue each year.

How many employees does Creo Medical have?

Creo Medical employs 175 workers across the globe.

What is Creo Medical's official website?

The official website for Creo Medical is creomedical.com.

How can I contact Creo Medical?

The company can be reached via phone at +44-1291-606005.


This page was last updated on 5/7/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.